- Published: Saturday, 25 March 2017 13:49
- Published: Monday, 20 March 2017 11:01
Wed, March 22, 2017 Celebrate Three Decades of Determination with the present floor of ACTUP, our alumni, allies and friends. tickets are $0 to $300 for attendees. Visit Eventbrite or or bring your donation to the door Cash or Credit Card.
6:00 PM – 9:00 PM EDT Add to Calendar
Keith D. Cylar House
747 E 9th St
New York, NY 10009 View Map
Celebrate Three Decades of Determination with the present floor of ACTUP, our alumni, allies and friends.
Tickets to Hamilton and Anastasia, When We Rise signed script, United in Anger DVDs, How to Survive a Plague books.
Recent and remote ACTUP video and imagery
Food, Drink, ACTUP comrades!
Guests of Honor:
Gerri Wells -- Eric Sawyer -- Andy Velez
Original ACTUP members, who answered that first call to action by meeting immediately : Inspiring an entire generation in their wake.
Come help them celebrate the work and retirement of Jim Eigo:
Founding member of the Treatment and Data committee of ACTUP which brought about fundamental changes in AIDS drug research and regulation -- inserting real community input into drugtrials, transforming drug availability and ultimately enabling combination therapy.
Jim returned to the floor of ACTUP in 2013, and co-founded the Prevention of HIV Action Group (PHAG), the renascent ACTUP committee which loudly and forcefully demanded embrace ofPrEP, PEP and TAsP for HIV prevention.
He helped to drive the cornerstone of prevention into the Blueprint to End AIDS in New York State.
His vision of DOHMH Sexual Health Clinics as full-service hubs of HIV prevention and care, should help to change the way folks at risk for HIV are approached, tested, and followed-up.
We will also feature the ongoing roll-out of Legacee Kares, an app for homeless and underprivileged youth focused on connecting them to human service and HIV resources. It was developedwith the help of ACTUP’s current Youth and Homelessness working group.
PLUS: Learn a new twist on a classic chant.
ACTUP! FIGHT BACK!! END AIDS!!!
- Published: Tuesday, 07 February 2017 08:41
ACTIVISTS AROUND THE WORLD MARCH #ForTobeka
- Demonstrations held at Roche & pharma associations in South Africa, Malaysia, UK, France, Zambia, Brazil, US
- 108 organisations endorse a letter to Roche
Tuesday, 7th February 2017 – Swiss multinational company Roche faced global condemnation today from women living with cancer, families of people with cancer, activists, scientists, researchers and health professionals from across the world. They highlighted the immoral and unconscionable tactics employed by Roche across the developed and developing world. Roche’s greed is preventing women from accessing affordable versions of trastuzumab, an essential medicine used in the treatment of breast cancer.
The global day of action was led by women living with cancer in South Africa who gathered outside Roche’s office in Johannesburg demanding justice for Tobeka Daki – a leading cancer activist from South Africa whose own struggle against cancer ended last year.
“In South Africa today, we launched the Tobeka Daki Campaign for Access to Trastuzumab
in loving memory of a fearless activist who lead our struggle to ensure women could get this medicine,” said Salomé Meyer of the Cancer Alliance in South Africa. “Even as the likelihood of her being able to get trastuzumab diminished, Tobeka’s determination to ensure other women could access the medicine only grew stronger.”
Despite being a good candidate for trastuzumab, Tobeka was never able to access the treatment due to its high cost. In South Africa the annual price charged by Roche in the private sector is around US$ 38,365 (ZAR 516,700). The few public facilities which can access trastuzumab do so at a lower price of around US$ 15,735 (ZAR 211,920) per year. But, health economists have shown that a year’s worth of trastuzumab can be produced and sold for only US$ 240, a price that includes a 50% increase above the cost of production for profit.
Roche maintains its high prices in every way possible. Roche holds multiple evergreened patents on trastuzumab in certain countries across the world. In South Africa, for example, multiple patents extend Roche’s monopoly until 2033. In countries where the patents expired or do not exist, Roche is using other means to block potentially more affordable biosimilar versions coming to market.
- Published: Tuesday, 07 February 2017 12:38
7th February 2017
Today we stand together as women living with cancer, families of people with cancer, activists, scientists, researchers and health professionals from across the world. Together we demand that no woman go without it lifesaving breast cancer treatment because it is too expensive.
(Click photo for hi-res image)
We demand justice for Tobeka Daki.
A fearless activist from South Africa who was living with HER2+ breast cancer since 2013. Despite being a good candidate for trastuzumab, Tobeka was never able to access the treatment due to its high cost.
On 14 November 2016 she died in her home.
We do not know whether trastuzumab would have saved Tobeka’s life – trastuzumab doesn’t always work. We do know, however, that Tobeka was never given a chance. Even though she was dying and the medicine existed, she was never given an opportunity to try it.
The price of trastuzumab varies in countries across the world. These prices aren’t always public. They are agreed behind closed doors.
In South Africa the annual price in the private sector is around US$ 38,365. The few public facilities which can access trastuzumab do so at a lower price of around US$ 15,735 per year. Both out of reach of most.
- In Brazil it costs US$ 17,562.
- In Malaysia it costs US$ 17,929.
- In France it costs US$ 30,595.
- In India it costs US$ 10,938*.
But, health economists have shown that a year’s worth of trastuzumab can be produced and sold for only US$ 240. Drastically less. This estimated price even includes a 50% increase above the cost of production for profit.
Meanwhile Roche are posting fat profits.
In 2015 Roche made US$ 8.9-billion profit. In the same year CEO Severin Schwan earned US$ 12-million. It seems highly plausible that Roche could cut the price of trastuzumab dramatically and still be very profitable.
Instead Roche maintains it’s high prices in any way possible. Roche holds multiple evergreened patents on trastuzumab in certain countries across the world. In South Africa, for example, multiple patents extend their monopoly until 2033.
In countries where the patents have ended or do not exist, Roche is using other means to block potentially more affordable biosimilar versions coming to market. In India Roche have initiated a court challenge against the Indian regulatory body for its decision to approve Mylan’s version as a biosimilar product.
In Brazil and Argentina, Roche is one of the pharmaceutical companies litigating against those governments for their attempts to use legal international safeguards to protect public health.
For countries like the UK and the US, Roche are trying to charge a price for T-DM1, the drug breast cancer patients need once trastuzumab fails, that is so high even they cannot afford it.
For too long Roche has been allowed to charge exorbitant prices for these lifesaving treatments.
Tobeka had one life. Her two children had one mother. We had the means to give her a chance at survival and we failed her – as we will continue to fail other women.
What is most disturbing is the unconcerned attitude and the lack of basic humanity shown by people at Roche. It is not as if they are unaware that many people can’t access trastuzumab because of its high price.
Shame on you Manfred Heinzer (Roche South Africa General Manager) for not having done more since hearing about Tobeka’s plight six months before her death.
Shame on you Severin Schwan (Roche CEO) for insisting on fat profits while you could save lives by trimming your profits.
You could have given Tobeka a chance, but instead you turned your back on her.
Don’t turn your back on all the other women across the world.
WE DEMAND THAT ROCHE:
- Drop the price of trastuzumab and T-DM1 so that all women living with HER2+ breast cancer who need